Nathen Fuentes
Finanzdirektor/CFO bei TELOMIR PHARMACEUTICALS, INC.
Vermögen: 687 711 $ am 30.04.2024
Profil
Mr. Nathen Fuentes, CPA, is a Chief Financial Officer, Secretary & Treasurer at Telomir Pharmaceuticals, Inc. Mr. Fuentes was previously employed as a Chief Financial Officer by Emergence Health Holdings, a Chief Financial Officer by Divergent Dental Group LLC, a Chief Financial Officer by Family First Homecare, a Chief Financial Officer & Partner by Dermatology Medical Partners LLC, a Controller by Glytec LLC, and an Associate by PricewaterhouseCoopers LLP.
He received his undergraduate degree from the University of Florida and a graduate degree from Fairfield University.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
29.03.2024 | 101 134 ( 0,34% ) | 687 711 $ | 30.04.2024 |
Aktive Positionen von Nathen Fuentes
Unternehmen | Position | Beginn |
---|---|---|
TELOMIR PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 21.09.2023 |
Ehemalige bekannte Positionen von Nathen Fuentes
Unternehmen | Position | Ende |
---|---|---|
Emergence Health Holdings
Emergence Health Holdings Medical/Nursing ServicesHealth Services Emergence Health Holdings provides urgent healthcare services. The private company is based in Concord, NH. | Finanzdirektor/CFO | 01.09.2023 |
Glytec LLC
Glytec LLC Packaged SoftwareTechnology Services Part of Aseko, Inc., Glytec LLC is a healthcare provider company that specializes in improving the quality and cost of care for diabetes patients. The company, founded in 2006 by Robby Booth, is based in Waltham, MA, and has Edmond L. Furlong as its CEO since 2018. Glytec's FDA-cleared titration software and proprietary algorithms deliver personalized diabetes treatment recommendations across the continuum of care, from hospital to home. The company's eGlycemic Management System (eGMS) is an EHR-integrated cloud-based software solution that supports safe and effective glycemic management and insulin dosing. Glytec supports the transition from sliding scale to basal bolus insulin for standardization of insulin therapy across critical and non-critical care settings. The safety and efficacy of Glytec's solutions have been validated by several dozen studies published in medical journals and presented at scientific conferences. | Comptroller/Controller/Auditor | 01.01.2017 |
Ausbildung von Nathen Fuentes
University of Florida | Undergraduate Degree |
Fairfield University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
TELOMIR PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Commercial Services |
Emergence Health Holdings
Emergence Health Holdings Medical/Nursing ServicesHealth Services Emergence Health Holdings provides urgent healthcare services. The private company is based in Concord, NH. | Health Services |
Glytec LLC
Glytec LLC Packaged SoftwareTechnology Services Part of Aseko, Inc., Glytec LLC is a healthcare provider company that specializes in improving the quality and cost of care for diabetes patients. The company, founded in 2006 by Robby Booth, is based in Waltham, MA, and has Edmond L. Furlong as its CEO since 2018. Glytec's FDA-cleared titration software and proprietary algorithms deliver personalized diabetes treatment recommendations across the continuum of care, from hospital to home. The company's eGlycemic Management System (eGMS) is an EHR-integrated cloud-based software solution that supports safe and effective glycemic management and insulin dosing. Glytec supports the transition from sliding scale to basal bolus insulin for standardization of insulin therapy across critical and non-critical care settings. The safety and efficacy of Glytec's solutions have been validated by several dozen studies published in medical journals and presented at scientific conferences. | Technology Services |